Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens

Clinical Infectious Diseases

Volumn 32, Issue 6, 2001, Pages 963-969

  Hoff, J�r�me ^a   Bani Sadr, Firouze ^a   Gassin, Mich�le ^b   Raffi, Fran�ois ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE BIOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; DELAVIRDINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS DNA; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG EFFECT; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LYMPHOCYTE COUNT; MALE; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT DISEASE; SEROCONVERSION; VIRUS DETECTION; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 0035867080     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/319368     Document Type: Article

References (40)

1. The interaction of human immunodeficiency virus infection and hepatitis B virus infection in infected homosexual men
2. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state
3. Reactivation of hepatitis B in AIDS
4. Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection
5. Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses
6. Hepatitis B virus
7. Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV)
8. Interactions between human immunodeficiency virus-1, hepatitis delta virus, and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus
9. Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B
10. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis
11. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
12. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor
13. High-level resistance to (-) enantiomeric 2�-deoxy-3�-thlacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase
14. Inhibition of the replication of hepatitis B virus in vitro by 2�,3�-dideoxy-3�-thiacytidine and related analogues
15. A preliminary trial of lamivudine for chronic hepatitis B infection
16. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
17. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
18. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
19. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
20. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
21. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns
22. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men
23. Hepatitis B and hepatitis D
24. Classification of chronic hepatitis: Diagnosis, grading, and staging
25. The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw
26. Vaccine-induced escape mutant of hepatitis B virus
27. Detection of hepatitis B virus
28. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HW infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party
29. Interferon-alpha-2a: A review of its pharmacological properties and therapeutic use in the management of viral hepatitis
30. Hepatitis B reactivation after lamivudine
31. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study
32. Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: Evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy
33. Treatment of chronic hepatitis B infection
34. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation
35. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
36. Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene
37. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation
38. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: Hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss
39. Dynamics of hepatitis B virus infection in vivo
40. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro